Skip to main content

Osimertinib and Stereotactic Body Radiation Therapy in Treating Patients with EGFR Mutant Advanced Non-small Cell Lung Cancer

Trial Status: Active

This phase II trial studies the how well osimertinib works when given together with stereotactic body radiation therapy in treating patients with EGFR mutant non-small cell lung cancer that has spread to other places in the body (advanced). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving osimertinib and stereotactic body radiation therapy may work better in treating patients with advanced non-small lung cancer.

Inclusion Criteria

  • Written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure. However, the Investigator should not repeat procedures that are performed as part of standard of care (SOC), if they are within the screening window and are done prior to signing the informed consent form (ICF)
  • Advanced EGFR exon 19 or 21 mutant non-small cell lung cancer (NSCLC), not amenable to curative surgery or radiotherapy. EGFR mutations may be demonstrated by standard, clinically accepted methods, including direct gene sequencing, polymerase chain reaction (PCR), and next generation (NextGen) sequencing
  • World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Patients must have a life expectancy >= 12 weeks
  • Females should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening: * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments * Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range for the institution * Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
  • Male patients should be willing to use barrier contraception
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • At least one lesion, not previously irradiated, that can be accurately assessed at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements
  • Absolute neutrophil count > 1.5 x 10^9/L
  • Platelet count > 100 x 10^9/L
  • Hemoglobin > 9.0 g/dL (transfusion is permitted to achieve hemoglobin [Hgb] >= 9.0 g/dL)
  • Alanine aminotransferase < 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or < 5 times ULN in the presence of liver metastases
  • Aspartate aminotransferase < 2.5 times ULN if no demonstrable liver metastases or < 5 times ULN in the presence of liver metastases
  • Total bilirubin < 1.5 times ULN if no liver metastases or < 3 times ULN in the presence of documented Gilbert’s syndrome (unconjugated hyperbilirubinemia) or liver metastases
  • Serum creatinine < 1.5 times ULN concurrent with creatinine clearance > 50 ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is > 1.5 times ULN

Exclusion Criteria

  • Involvement in the planning and/or conduct of the study (applies to both sponsor staff and/or staff at the study site)
  • Previous treatment with osimertinib or any EGFR tyrosine kinase inhibitors (TKI)
  • Previous treatment with immunotherapy or any check point inhibitors
  • Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater
  • Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 week prior). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4
  • Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum therapy related neuropathy
  • Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required
  • Patients with spinal cord compression, symptomatic and unstable brain metastases except for those patients who have completed definitive therapy, and have had a stable neurological status for at least 2 weeks after completion of definitive therapy. Patients may be on corticosteroids to control brain metastases if they have been on a stable dose for 2 weeks (14 days) prior to the start of study treatment and are clinically asymptomatic
  • Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
  • Any of the following cardiac criteria: * Mean resting corrected QT interval (QTc using Fridericia’s formula) > 470 msec * Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiography (ECG) (e.g., complete left bundle branch block, third degree heart block, second degree heart block) * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: serum/plasma potassium < lower limit of normal [LLN]; serum/plasma magnesium < LLN; serum/plasma calcium < LLN, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointe
  • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib
  • History of hypersensitivity to osimertinib (or drugs with a similar chemical structure or class to osimertinib) or any excipients of these agents
  • Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements
  • Previous allogeneic bone marrow transplant


City of Hope Comprehensive Cancer Center
Status: ACTIVE
Contact: Sagus Sampath
Phone: 626-256-4673


UT Southwestern / Simmons Cancer Center-Dallas
Status: ACTIVE
Contact: Sawsan Rashdan
Phone: 214-648-4180


I. To determine the efficacy of osimertinib plus stereotactic body radiation therapy (SABR) in patients with EGFR mutant lung cancer.


I. To determine the impact of osimertinib plus SABR on survival.

II. To determine the impact of osimertinib plus SABR on length of response.

III. To determine the impact of osimertinib plus SABR on the length of time until next therapy needed.

IV. To determine the impact of osimertinib plus SABR on tumor response.

V. To determine the impact of osimertinib plus SABR on the duration of time while on osimertinib.

VI. Demonstrate safety of osimertinib followed by SABR.


I. To improve understanding of the molecular changes that occur during the process of osimertinib resistance.


Patients receive osimertinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. After course 2, patients stop osimertinib for 3 days and undergo SABR. Beginning 3 days after SABR, patients receive osimertinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
UT Southwestern / Simmons Cancer Center-Dallas

Principal Investigator
Sawsan Rashdan

  • Primary ID SCCC-02518; STU 122017-017
  • Secondary IDs NCI-2018-02202
  • ID NCT03667820